These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 33588655)

  • 1. An adaptive seamless Phase 2-3 design with multiple endpoints.
    Jin M; Zhang P
    Stat Methods Med Res; 2021 Apr; 30(4):1143-1151. PubMed ID: 33588655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extensions of the 2-in-1 adaptive design.
    Chen C; Li W; Deng Q
    Contemp Clin Trials; 2020 Aug; 95():106053. PubMed ID: 32504820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 2-in-1 adaptive phase 2/3 design for expedited oncology drug development.
    Chen C; Anderson K; Mehrotra DV; Rubin EH; Tse A
    Contemp Clin Trials; 2018 Jan; 64():238-242. PubMed ID: 28966137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An extension to a 2-in-1 adaptive design with biomarker subpopulation selection.
    Jin M; Zhang P
    Contemp Clin Trials; 2023 Jun; 129():107209. PubMed ID: 37116646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A gated group sequential design for seamless Phase II/III trial with subpopulation selection.
    Miao G; Liao JJZ; Yang J; Anderson K
    BMC Med Res Methodol; 2023 Jan; 23(1):2. PubMed ID: 36597042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adaptive design implementation in confirmatory trials: methods, practical considerations and case studies.
    Li Q; Lin J; Lin Y
    Contemp Clin Trials; 2020 Nov; 98():106096. PubMed ID: 32739496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.
    Jenkins M; Stone A; Jennison C
    Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 2-in-1 adaptive design to seamlessly expand a selected dose from a phase 2 trial to a phase 3 trial for oncology drug development.
    Zhang P; Li XN; Lu K; Wu C
    Contemp Clin Trials; 2022 Nov; 122():106931. PubMed ID: 36174958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RESTART trial design: two-stage seamless transition design with operational considerations.
    Yi M; Zhuo B; Cooner F
    J Biopharm Stat; 2023 Nov; 33(6):820-829. PubMed ID: 36653753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A seamless phase IIB/III adaptive outcome trial: design rationale and implementation challenges.
    Chen YH; Gesser R; Luxembourg A
    Clin Trials; 2015 Feb; 12(1):84-90. PubMed ID: 25278227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The extension of 2-in-1 adaptive phase 2/3 designs and its application in oncology clinical trials.
    Fan L; Zhao J; Li W
    Contemp Clin Trials; 2020 Nov; 98():106148. PubMed ID: 32949732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimation of treatment effect in 2-in-1 adaptive design and some of its extensions.
    Li W; Bai X; Deng Q; Liu F; Chen C
    Stat Med; 2021 May; 40(11):2556-2577. PubMed ID: 33723865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of innovative two-stage seamless adaptive design with different endpoints and population shift.
    Mai W; Chow SC
    J Biopharm Stat; 2024 Mar; ():1-14. PubMed ID: 38515269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An adaptive seamless 2-in-1 design with biomarker-driven subgroup enrichment.
    Wu L; Lin J
    J Biopharm Stat; 2024 Apr; ():1-15. PubMed ID: 38651758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seamless phase 2/3 oncology trial design with flexible sample size determination.
    Teng Z; Tian Y; Liu Y; Liu G
    Stat Med; 2020 Aug; 39(18):2373-2386. PubMed ID: 32338410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptive seamless designs with interim treatment selection: a case study in oncology.
    Carreras M; Gutjahr G; Brannath W
    Stat Med; 2015 Apr; 34(8):1317-33. PubMed ID: 25640198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology.
    Hobbs BP; Barata PC; Kanjanapan Y; Paller CJ; Perlmutter J; Pond GR; Prowell TM; Rubin EH; Seymour LK; Wages NA; Yap TA; Feltquate D; Garrett-Mayer E; Grossman W; Hong DS; Ivy SP; Siu LL; Reeves SA; Rosner GL
    J Natl Cancer Inst; 2019 Feb; 111(2):118-128. PubMed ID: 30561713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A variation of a 2-in-1 adaptive design to seamlessly expand a selected dose from a phase 2 trial to a phase 3 trial for oncology drug development.
    Zhang P; Li XN; Lu K; Wu C; Ge M
    Contemp Clin Trials; 2023 Apr; 127():107119. PubMed ID: 36804045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A parametric multiple test procedure to adaptive group-sequential trials allowing for mid-term modifications.
    Jin M
    Contemp Clin Trials; 2020 Mar; 90():105955. PubMed ID: 32028024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flexible seamless 2-in-1 design with sample size adaptation.
    Li R; Wu L; Liu R; Lin J
    J Biopharm Stat; 2024 Mar; ():1-19. PubMed ID: 38549502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.